Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington’s disease: a claims‑based retrospective cohort study

References

• Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005. doi: 10.1038/nrdp.2015.5.
   PubMed Web of Science ®Google Scholar
• Roos RA. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5(5):40. doi: 10.1186/1750-1172-5-40.
   PubMedGoogle Scholar
• Quarrell OWJ, Nance MA, Nopoulos P, et al. Managing juvenile Huntington’s disease. Neurodegener Dis Manag. 2013;3(3):267–276. doi: 10.2217/nmt.13.18.
   Google Scholar
• Lipe H, Bird T. Late onset huntington disease: clinical and genetic characteristics of 34 cases. J Neurol Sci. 2009;276(1–2):159–162. doi: 10.1016/j.jns.2008.09.029.
   PubMed Web of Science ®Google Scholar
• Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204–216. doi: 10.1038/nrneurol.2014.24.
   PubMed Web of Science ®Google Scholar
• Keum JW, Shin A, Gillis T, et al. The HTT CAG-expansion mutation determines age at death but not disease duration in huntington disease. Am J Hum Genet. 2016;98(2):287–298. doi: 10.1016/j.ajhg.2015.12.018.
   PubMed Web of Science ®Google Scholar
• Carlozzi NE, Tulsky DS. Identification of health-related quality of life (HRQOL) issues relevant to individuals with huntington disease. J Health Psychol. 2013;18(2):212–225. doi: 10.1177/1359105312438109.
   PubMed Web of Science ®Google Scholar
• Carlozzi NE, Boileau NR, Hahn EA, et al. Responsiveness to change over time: an examination of the Neuro-QoL social function measures in persons with huntington’s disease. J Huntingtons Dis. 2020;9(1):83–97. doi: 10.3233/JHD-190385.
   PubMed Web of Science ®Google Scholar
• Chaganti SS, McCusker EA, Loy CT. What do we know about late onset huntington’s disease? J Huntingtons Dis. 2017;6(2):95–103. doi: 10.3233/JHD-170247.
   PubMedGoogle Scholar
• Myers RH, Sax DS, Schoenfeld M, et al. Late onset of huntington’s disease. J Neurol Neurosurg Psychiatry. 1985;48(6):530–534. doi: 10.1136/jnnp.48.6.530.
   PubMed Web of Science ®Google Scholar
• Foroud T, Gray J, Ivashina J, et al. Differences in duration of huntington’s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66(1):52–56. doi: 10.1136/jnnp.66.1.52.
   PubMed Web of Science ®Google Scholar
• Koutsis G, Karadima G, Kladi A, et al. Late-onset huntington’s disease: diagnostic and prognostic considerations. Parkinsonism Relat Disord. 2014;20(7):726–730. doi: 10.1016/j.parkreldis.2014.03.017.
   PubMed Web of Science ®Google Scholar
• Volpi E, Terenzi F, Bagnoli S, et al. Late-onset huntington disease: an italian cohort. J Clin Neurosci. 2021;86:58–63. doi: 10.1016/j.jocn.2020.12.025.
   PubMed Web of Science ®Google Scholar
• Sipilä JOT, Kauko T, Päivärinta M, et al. Comparison of mid-age-onset and late-onset huntington’s disease in Finnish patients. J Neurol. 2017;264(10):2095–2100. doi: 10.1007/s00415-017-8600-2.
   PubMed Web of Science ®Google Scholar
• Ranganathan M, Kostyk SK, Allain DC, et al. Age of onset and behavioral manifestations in Huntington’s disease: an Enroll-HD cohort analysis. Clin Genet. 2021;99(1):133–142. doi: 10.1111/cge.13857.
   PubMed Web of Science ®Google Scholar
• Kwa L, Larson D, Yeh C, et al. Influence of age of onset on Huntington’s disease phenotype. Tremor Other Hyperkinet Mov. 2020;10:21. doi: 10.5334/tohm.536.
   PubMed Web of Science ®Google Scholar
• Anil M, Mason SL, Barker RA. The clinical features and progression of late-onset versus younger-onset in an adult cohort of Huntington’s disease patients. J Huntingtons Dis. 2020;9(3):275–282. doi: 10.3233/jhd-200404.
   PubMed Web of Science ®Google Scholar
• Oosterloo M, Bijlsma EK, van Kuijk SM, et al. Clinical and genetic characteristics of late-onset Huntington’s disease. Parkinsonism Relat Disord. 2019;61:101–105. doi: 10.1016/j.parkreldis.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Ma X, Gandhy R, Lu X, et al. editors. Clinical characteristics of late-onset Huntington’s disease in North Americans from Enroll-HD. 15th Annual Huntington’s Disease Therapeutics Conference; 2020; Palm Springs, CA, USA.
   Google Scholar
• Capiluppi E, Romano L, Rebora P, et al. Late-onset Huntington’s disease with 40-42 CAG expansion. Neurol Sci. 2020;41(4):869–876. doi: 10.1007/s10072-019-04177-8.
   PubMed Web of Science ®Google Scholar
• Hawton A, Green C, Goodwin E, et al. Health state utility values (QALY weights) for Huntington’s disease: an analysis of data from the European Huntington’s Disease Network (EHDN). Eur J Health Econ. 2019;20(9):1335–1347. doi: 10.1007/s10198-019-01092-9.
   PubMed Web of Science ®Google Scholar
• Paoli RA, Botturi A, Ciammola A, et al. Neuropsychiatric burden in Huntington’s disease. Brain Sci. 2017;7(12):67. doi: 10.3390/brainsci7060067.
   PubMedGoogle Scholar
• Thorley EM, Iyer RG, Wicks P, et al. Understanding how chorea affects health-related quality of life in Huntington disease: an online survey of patients and caregivers in the United States. Patient. 2018;11(5):547–559. doi: 10.1007/s40271-018-0312-x.
   PubMedGoogle Scholar
• Divino V, Dekoven M, Warner JH, et al. The direct medical costs of Huntington’s disease by stage. A retrospective commercial and Medicaid claims data analysis. J Med Econ. 2013;16(8):1043–1050. doi: 10.3111/13696998.2013.818545.
   PubMedGoogle Scholar
• Bachoud-Levi AC, Ferreira J, Massart R, et al. International guidelines for the treatment of Huntington’s disease. Front Neurol. 2019;10:710. doi: 10.3389/fneur.2019.00710.
   PubMed Web of Science ®Google Scholar
• Exuzides A, Reddy SR, Chang E, et al. Healthcare utilization and cost burden of Huntington’s disease among medicare beneficiaries in the United States. J Med Econ. 2021;24(1):1327–1336. doi: 10.1080/13696998.2021.2002579.
   PubMed Web of Science ®Google Scholar
• To TM, Exuzides A, Abbas IM, et al. Healthcare resource utilization and costs among individuals with versus without Huntington’s disease in a US population. J Manag Care Spec Pharm. 2022;28(11):1228–1239.
   PubMed Web of Science ®Google Scholar
• Exuzides A, To TM, Abbass IM, et al. Healthcare resource utilization and costs in individuals with Huntington’s disease by disease stage in a US population. J Med Econ. 2022;25(1):722–729. doi: 10.1080/13696998.2022.2076997.
   PubMed Web of Science ®Google Scholar
• IBM Watson Health. IBM MarketScan research databases white paper for life sciences researchers. 2020 [cited 2022 October 28]. Available from: https://www.ibm.com/products/marketscan-research-databases/resources.
   Google Scholar
• Julayanont P, McFarland NR, Heilman KM. Mild cognitive impairment and dementia in motor manifest Huntington’s disease: classification and prevalence. J Neurol Sci. 2020;408:116523. doi: 10.1016/j.jns.2019.116523.
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Measuring price change in the CPI: medical care. 2020 [cited 2022 October 28]. Available from: https://www.bls.gov/cpi/factsheets/medical-care.htm.
   Google Scholar
• Neelon B, O'Malley AJ, Smith VA. Modeling zero-modified count and semicontinuous data in health services research part 1: background and overview. Stat Med. 2016;35(27):5070–5093. doi: 10.1002/sim.7050.
   PubMed Web of Science ®Google Scholar
• Jones C, Busse M, Quinn L, et al. The societal cost of Huntington’s disease: are we underestimating the burden? Eur J Neurol. 2016;23(10):1588–1590. doi: 10.1111/ene.13107.
   PubMed Web of Science ®Google Scholar
• Frich JC, Rae D, Roxburgh R, et al. Health care delivery practices in Huntington’s disease specialty clinics: an international survey. J Huntingtons Dis. 2016;5(2):207–213. doi: 10.3233/JHD-160192.
   PubMedGoogle Scholar
• Johnson EK, Nelson CP. Values and pitfalls of the use of administrative databases for outcomes assessment. J Urol. 2013;190(1):17–18. doi: 10.1016/j.juro.2013.04.048.
   PubMed Web of Science ®Google Scholar
• Anderson KE, Divino V, DeKoven M, et al. Interventional differences among Huntington’s disease patients by disease progression in commercial and medicaid populations. J Huntingtons Dis. 2014;3(4):355–363. doi: 10.3233/jhd-140124.
   PubMedGoogle Scholar
• Sung VW, Iyer RG, Gandhi SK, et al. Retrospective analysis of healthcare resource use, treatment patterns, and treatment-related events in patients with Huntington’s disease–associated chorea initiated on tetrabenazine. J Health Econ Outcomes Res. 2018;6(1):15–24. doi: 10.36469/9779.
   PubMedGoogle Scholar
• Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488–495. doi: 10.1097/EDE.0b013e3181a819a1.
   PubMed Web of Science ®Google Scholar
• Mentzel T, Lieverse R, Levens A, et al. Reliability and validity of an instrument for the assessment of bradykinesia. Psychiatry Res. 2016;238:189–195. doi: 10.1016/j.psychres.2016.02.011.
   PubMed Web of Science ®Google Scholar
• di Biase L, Summa S, Tosi J, et al. Quantitative analysis of bradykinesia and rigidity in Parkinson’s disease. Front Neurol. 2018;9:121. doi: 10.3389/fneur.2018.00121.
   PubMed Web of Science ®Google Scholar